In addition, microarry analysis has revealed that the degree of OCT1 expression can be variable when comparing tumor vs. normal human tissues, suggesting that therapeutic responses to metformin in cancer patients may differ depending on their tumor-type [76]. Here, SLC22A1 is linked to neoplasm.